Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2021 from OUS - Department of Cancer Genetics
9 publications found
Re-defining synthetic lethality by phenotypic profiling for precision oncology
Cell Chem Biol (in press)
DOI 10.1016/j.chembiol.2021.01.026, PubMed 33631125
miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer
PLoS Comput Biol, 17 (2), e1008608
DOI 10.1371/journal.pcbi.1008608, PubMed 33566819
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women
N Engl J Med, 384 (5), 428-439
DOI 10.1056/NEJMoa1913948, PubMed 33471991
Efficient gene expression signature for a breast cancer immuno-subtype
PLoS One, 16 (1), e0245215
DOI 10.1371/journal.pone.0245215, PubMed 33434192
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
Sci Adv, 7 (8)
DOI 10.1126/sciadv.abe4038, PubMed 33608276
In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study
Breast Cancer Res, 23 (1), 17
DOI 10.1186/s13058-021-01393-z, PubMed 33526044
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016
Artificial intelligence, machine learning, and drug repurposing in cancer
Expert Opin Drug Discov, 1-13 (in press)
DOI 10.1080/17460441.2021.1883585, PubMed 33543671
High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers
Mol Oncol, 15 (2), 429-461
DOI 10.1002/1878-0261.12850, PubMed 33176066